This led to the commercialisation in women with severe gonadotrophin deficiency (hypogonadotrophic hypogonadism), of a product with a 2:1 FSH: LH preparation – in effect a recombinant ‘Pergogreen’. Here, BRD2 is linked to hypogonadotropic hypogonadism.